Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Nasr on the Need for Preclinical Models of Prostate Cancer Dormancy

April 26th 2023

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy

April 26th 2023

Drs Manning and Armstrong discuss the best treatment approaches for a patient with mCRPC and disease progression in the bone after initial radiotherapy for metastatic disease.

Patient Profile: A 78-Year-Old Man with mCRPC

April 26th 2023

Dr Andrew Armstrong presents a profile of a 78-year-old man with mCRPC with a single PSMA-avid bone metastasis and asks Dr Manning how he would treat the patient in question.

Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE

April 26th 2023

A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.

mHSPC: Use of Triplet Therapy

April 26th 2023

Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.

FDA Grants Fast Track Designation to 177Lu-PNT2002 for mCRPC

April 25th 2023

The FDA has granted a fast track designation to 177Lu-PNT2002 for the treatment of patients with metastatic castration-resistant prostate cancer.

Niraparib/Abiraterone Acetate Combo Approved in Europe for BRCA1/2+ mCRPC

April 24th 2023

The European Commission has granted marketing authorization to the dual action tablet comprised of niraparib and abiraterone acetate to be administered with prednisone or prednisolone in adult patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.

Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

April 19th 2023

A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.

Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer

April 19th 2023

Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.

CYCLONE 1 Misses Primary End Point But Abemaciclib Shows Activity in mCRPC

April 18th 2023

Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.

Approved Treatment Options for Patients with mCRPC

April 17th 2023

Medical oncologist Andrew Armstrong, MD, details the available treatment options for patients with mCRPC, and how recommendations vary by prior therapy and mutation status.

The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

April 17th 2023

Andrew Armstrong, MD, and Matthew Manning, MD, explain how the treatment options and typical patient outcomes in mCRPC have changed over history.

Optimizing Care for Patients With Non-metastatic CRPC

April 12th 2023

Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.

Non-metastatic Castration-Resistant Prostate Cancer: Patient Monitoring Strategies

April 12th 2023

Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.

NICE Guidance Supports Olaparib Use in BRCA-Mutant Breast, Prostate Cancer

April 7th 2023

The National Institute for Health and Care Excellence announced final draft guidance recommending the PARP inhibitor olaparib for patients with HER2-negative, high-risk early breast cancer harboring a BRCA1/2 mutation, as well as for those with previously treated hormone-relapsed metastatic prostate cancer with a BRCA1/2 mutation.

Importance of Quality of Life When Choosing Therapy for nmCRPC

April 5th 2023

A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.

AR Inhibitors in nmCRPC: Real-World Data

April 5th 2023

Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.

Dr Tombal on the Pharmacokinetics of Darolutamide Plus Docetaxel in mHSPC

April 4th 2023

Bertrand Tombal, MD, PhD, discusses the pharmacokinetics of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer.

Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer

April 3rd 2023

Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.

TALAPRO-2 Data Underscore Potential of Talazoparib Plus Enzalutamide in mCRPC

March 29th 2023

Neeraj Agarwal, MD, discusses preclinical data that supported the launch of the TALAPRO-2 trial and key efficacy and safety data on the use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer irrespective of homologous recombination repair mutational status.